In vitro antifungal susceptibility of Malassezia furfur from bloodstream infections
- 1 November 2014
- journal article
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 63 (11) , 1467-1473
Abstract
Fungaemia caused by Malassezia spp. in hospitalized patients requires prompt and appropriate therapy, but standard methods for the definition of the in vitro antifungal susceptibility have not been established yet. In this study, the in vitro susceptibility of Malassezia furfur from bloodstream infections (BSIs) to amphotericin B (AMB), fluconazole (FLC), itraconazole (ITC), posaconazole (POS) and voriconazole (VRC) was assessed using the broth microdilution (BMD) method of the Clinical and Laboratory Standards Institute (CLSI) with different media such as modified Sabouraud dextrose broth (SDB), RPMI and Christensen’s urea broth (CUB). Optimal broth media that allow sufficient growth of M. furfur, and produce reliable and reproducible MICs using the CLSI BMD protocol were assessed. Thirty-six M. furfur isolates collected from BSIs of patients before and during AMB therapy, and receiving FLC prophylaxis, were tested. A good growth of M. furfur was observed in RPMI, CUB and SDB at 32 °C for 48 and 72 h. No statistically significant differences were detected between the MIC values registered after 48 and 72 h incubation. ITC, POS and VRC displayed lower MICs than FLC and AMB. These last two antifungal drugs showed higher and lower MICs, respectively, when the isolates were tested in SDB. SDB is the only medium in which it is possible to detect isolates with high FLC MICs in patients receiving FLC prophylaxis. A large number of isolates showed high AMB MIC values regardless of the media used. In conclusion, SDB might be suitable to determine triazole susceptibility. However, the media, the drug formulation or the breakpoints herein applied might not be useful for assessing the AMB susceptibility of M. furfur from BSIs.Keywords
This publication has 25 references indexed in Scilit:
- The Malassezia Genus in Skin and Systemic DiseasesClinical Microbiology Reviews, 2012
- In vitro susceptibility of fluconazole-susceptible and -resistant isolates of Malassezia pachydermatis against azolesVeterinary Microbiology, 2011
- Malassezia furfur fungaemia in a neonatal patient detected by lysis‐centrifugation blood culture method: first case reported in ItalyMycoses, 2011
- Advances in the identification of MalasseziaMolecular and Cellular Probes, 2011
- Minireview:Malasseziainfections in immunocompromised patientsMycoses, 2010
- In Vitro Activity of Seven Systemically Active Antifungal Agents against a Large Global Collection of RareCandidaSpecies as Determined by CLSI Broth Microdilution MethodsJournal of Clinical Microbiology, 2009
- A Modified Christensen's Urea and CLSI Broth Microdilution Method for Testing Susceptibilities of SixMalasseziaSpecies to Voriconazole, Itraconazole, and KetoconazoleJournal of Clinical Microbiology, 2006
- Use of Fatty Acid RPMI 1640 Media for Testing Susceptibilities of Eight Malassezia Species to the New Triazole Posaconazole and to Six Established Antifungal Agents by a Modified NCCLS M27-A2 Microdilution Method and EtestJournal of Clinical Microbiology, 2004
- A Randomized and Blinded Multicenter Trial of High‐Dose Fluconazole plus Placebo versus Fluconazole plus Amphotericin B as Therapy for Candidemia and Its Consequences in Nonneutropenic SubjectsClinical Infectious Diseases, 2003
- Malassezia pachydermatis fungaemia in a neonatal intensive care unitActa Paediatrica, 2001